GLUE Company Profile and Key Details

Q: Who are the executives of GLUE?

Dr. Markus Warmuth M.D.Pres, Chief Executive Officer & DirectorDr. Filip Janku M.D., Ph.D.Chief Medical OfficerDr. Sharon Townson Ph.D.Chief Technology OfficerDr. Owen B. Wallace Ph.D.Chief Scientific OfficerMr. Magnus Walter DPHILSenior Vice President of Chemical Sciences & Process Devel.Dr. John C. Castle Ph.D.Chief Data ScientistMs. Jennifer ChampouxChief People & Operations OfficerDr. Jullian G. Jones J.D., M.B.A., Ph.D.Chief Bus. OfficerMr. Ajim A. Tamboli C.F.A.Chief Financial OfficerMr. Phil Nickson J.D., Ph.D.Gen. CounselDr. Silvia Buonamici Ph.D.Senior Vice President of Drug Discovery BiologyMr. Philip Nickson J.D., Ph.D.Gen. Counsel

NASDAQ : GLUE

Monte Rosa Therapeutics

$24.20

0.3+1.26%

At Close 4:00 PM

68.69

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Monte Rosa Therapeutics, Inc. (GLUE) stock surged +1.26%, trading at $24.20 on NASDAQ, up from the previous close of $23.90. The stock opened at $24.20, fluctuating between $23.46 and $24.75 in the recent session.

Stock Snapshot

23.9

Prev. Close

1.58B

Market Cap

23.4621

Day Low

-16.46

P/E Ratio

-1.47

EPS (TTM)

-1.1

Cash Flow per Share

24.2

Open

65.12M

Number of Shares

24.75

Day High

74.77%

Free Float in %

3.15

Book Value

1.78M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 30, 2026	23.75	24.75	23.46	24.20	2.33M
Jun 29, 2026	22.57	23.98	22.16	23.90	1.84M
Jun 26, 2026	21.66	22.37	20.92	22.29	5.92M
Jun 25, 2026	20.74	22.33	20.40	21.66	1.77M
Jun 24, 2026	21.00	22.15	20.63	20.85	2.29M
Jun 23, 2026	18.41	20.99	18.38	20.71	1.75M
Jun 22, 2026	19.00	19.23	17.91	18.67	1.79M
Jun 18, 2026	19.07	19.31	17.91	18.31	2.51M
Jun 17, 2026	17.93	19.22	17.93	18.41	1.18M
Jun 16, 2026	18.04	18.50	17.38	17.76	790.75K
Jun 15, 2026	18.59	19.00	17.88	18.12	745.3K
Jun 12, 2026	17.50	18.32	17.21	18.24	1.09M
Jun 11, 2026	16.54	17.31	16.39	17.10	1.39M
Jun 10, 2026	16.39	17.29	16.28	16.52	873.05K
Jun 09, 2026	17.39	17.83	16.15	16.61	832.82K
Jun 08, 2026	16.56	17.04	16.11	17.00	2.04M
Jun 05, 2026	17.45	17.80	16.25	16.37	949.04K
Jun 04, 2026	17.48	18.07	17.09	17.36	729.62K
Jun 03, 2026	17.87	18.02	17.30	17.59	882.11K
Jun 01, 2026	19.66	19.86	18.63	19.67	1.01M

Contact Details

Boston, MA 02210

United States

https://www.monterosatx.com 617 949 2643

About Company

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Stock Peers

ARGX

15.31+1.68%

argenx SE$927.77 REGN

-8.27-1.31%

Regeneron Pharmaceuticals, Inc.$623.54 UTHR

-3.09-0.57%

United Therapeutics Corporation$541.83 MDGL

9.67+1.83%

Madrigal Pharmaceuticals, Inc.$536.95 VRTX

-2.92-0.58%

Vertex Pharmaceuticals Incorporated$496.73 KRYS

-6.48-1.71%

Krystal Biotech, Inc.$371.67 PRAX

-15.77-4.50%

Praxis Precision Medicines, Inc.$334.79 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

2.05+0.65%

Ligand Pharmaceuticals Incorporated$316.09 ALNY

7.51+2.56%

Alnylam Pharmaceuticals, Inc.$301.03

Company Overview

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) closed at $24.20 USD, gaining $0.30 (1.26%) from the previous close of $23.90. The stock is currently mid-range between its 52-week high and low $4.12 and $25.77. With a market capitalization of about $1.58 billion, Monte Rosa Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.60). Key stats such as the average daily volume over the past year has been around 1.10 million shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Monte Rosa Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Markus Warmuth, the company employs approximately 142 people and listed since June 24, 2021. Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines.

Technical Performance

GLUE has shown sold momentum, gaining 3.04% over the past week and 143.18% over the past quarter, though year-to-date performance is up 55.87%. Short-term trend indicators are mixed aligned (SMA20 -4.22%, SMA50 -6.02%, SMA200 73.03%). The stock’s 14-day RSI is 43.66 (neutral), while the ATR of 1.3 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -28.21% below its high and over 428.56% above its low. Average 10-day trading volume of 2.53 million shares is significantly above the 3-month average of 1.12 million, indicating heightened recent market interest.

Valuation Metrics

Monte Rosa Therapeutics, Inc. trades at a P/E ratio of -12.96, slightly below the S&P 500 average, with a price-to-sales ratio of 36.54 and a price-to-book ratio of 3.03 trading at moderately above to book value. The P/FCF stands at -79.85, also below market averages.

Dividend & Fair Value

Monte Rosa Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $19.18. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Monte Rosa Therapeutics, Inc. generated EPS of $0.31 over the past year. Five-year average earnings growth is -41.09%. Wall Street analysts project EPS growth of -17.25% annually over the next five years. The latest quarter delivered EPS of -$0.45. The next quarter is forecast at -$0.34. Next year's EPS is expected at -$13.82. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 2 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $37.00 to $13.00. The high target offers 52.89% upside. The low target suggests -46.28% downside. The mean target is $28.25. This offers 16.74% upside. Monte Rosa Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 15.91%. The prior quarter beat by 53.61%. Over the last six quarters, Apple has recorded several small beats. These include -162.16% in March 20, 2025.

Shareholding & Insider Activity

Monte Rosa Therapeutics, Inc. has 61.76 million shares outstanding. The public float is 30.30 million shares, elevated short interest at 18.68% of float. This equals 8.70 million shares. The short ratio is 20.0 days. Institutional investors hold 101.16% of the float. Insiders own 0.73%. Behbahani Ali holds 7.69 million shares, Florence Anthony A. Jr. has 7.69 million shares and Landsman Liza has 7.69 million shares. Over the past six months, insider transactions show net selling. They sold 156.40 thousand shares across 26 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Monte Rosa Therapeutics has not generated any revenue. Returns are negative, with ROA at -44.56% and ROE at -75.51%.
On valuation metrics, Monte Rosa Therapeutics trades at a P/E of -12.96, P/S of 36.54 and P/B of 3.03. The current ratio is 9.54 and quick ratio is 9.54. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1381.98 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.07, supported by a cash flow-to-debt ratio of -0.38.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Monte Rosa Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $6.22M (margin 0.00%). Operating income was - $143.31M (margin 0.0%). Net income was- $135.35M (EPS - $2.63).
The company ended the quarter with $232.41M in cash and short-term investments, a total debt of $46.04M, and net debt of - $82.06M. Total assets were $303.76M, with equity of $179.25M. Financials further reflected weakness, with operating cash flow of - $43.80M, free cash flow of - $62.84M, and capital expenditures of - $19.04M.

Price Forecast & Outlook

Our AI price prediction model suggests that Monte Rosa Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.16%, with price expected at $25.69 by July 13, 2026, within a range of $24.53 to $26.77 3-Month Outlook: Projected fall of -42.77%, reaching $13.85 by September 25, 2026, with a range of $12.67 to $14.75. 1-Year Outlook: Projected gain of 6.53%, with price at $25.78 by June 29, 2027, within a range of $24.13 to $27.11.

Key Takeaways

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) shares are up 55.87% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Monte Rosa Therapeutics, Inc. trading at a premium to the broader market with a P/E of -12.96. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $20.14, suggesting -16.78% downside. Our AI forecast model points to short-term strength (6.16% over two weeks), a medium-term fall (-42.77% over three months), and a longer-term gain (6.53% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Monte Rosa Therapeutics, Inc. (GLUE) stock price?

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) stock price is $24.20 in the last trading session. During the trading session, GLUE stock reached the peak price of $24.75 while $23.46 was the lowest point it dropped to. The percentage change in GLUE stock occurred in the recent session was 1.26% while the dollar amount for the price change in GLUE stock was $0.30.

GLUE's industry and sector of operation?

The NASDAQ listed GLUE is part of Biotechnology industry that operates in the broader Healthcare sector. Monte Rosa Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GLUE?

Dr. Markus Warmuth M.D.
Pres, Chief Executive Officer & Director
Dr. Filip Janku M.D., Ph.D.
Chief Medical Officer
Dr. Sharon Townson Ph.D.
Chief Technology Officer
Dr. Owen B. Wallace Ph.D.
Chief Scientific Officer
Mr. Magnus Walter DPHIL
Senior Vice President of Chemical Sciences & Process Devel.
Dr. John C. Castle Ph.D.
Chief Data Scientist
Ms. Jennifer Champoux
Chief People & Operations Officer
Dr. Jullian G. Jones J.D., M.B.A., Ph.D.
Chief Bus. Officer
Mr. Ajim A. Tamboli C.F.A.
Chief Financial Officer
Mr. Phil Nickson J.D., Ph.D.
Gen. Counsel
Dr. Silvia Buonamici Ph.D.
Senior Vice President of Drug Discovery Biology
Mr. Philip Nickson J.D., Ph.D.
Gen. Counsel

How GLUE did perform over past 52-week?

GLUE's closing price is 487.38% higher than its 52-week low of $4.12 where as its distance from 52-week high of $25.77 is -6.09%.

How many employees does GLUE have?

Number of GLUE employees currently stands at 142.

Link for GLUE official website?

Official Website of GLUE is: https://www.monterosatx.com

How do I contact GLUE?

GLUE could be contacted at phone 617 949 2643 and can also be accessed through its website. GLUE operates from 645 Summer Street, Boston, MA 02210, United States.

How many shares of GLUE are traded daily?

GLUE stock volume for the day was 1.78M shares. The average number of GLUE shares traded daily for last 3 months was 1.1M.

What is the market cap of GLUE currently?

The market value of GLUE currently stands at $1.58B with its latest stock price at $24.20 and 65.12M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	142
Beta	1.6
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

GLUE Company Profile and Key Details

Monte Rosa Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook